<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531829</url>
  </required_header>
  <id_info>
    <org_study_id>BJCYH1893</org_study_id>
    <nct_id>NCT01531829</nct_id>
  </id_info>
  <brief_title>Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD</brief_title>
  <official_title>Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized，Multi-Center，Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In selected patients with acute pulmonary embolism(PE), low dose (50mg/2h) recombinant tissue
      plasminogen activator (rt-PA) regimen had been reported to have less bleeding tendency than
      the FDA-approved rt-PA 100mg/2h regimen 100mg/2h regimen (3% vs.10%), it is worthwhile to
      reveal whether low dose rt-PA plus low molecular weight heparin (LMWH) can rapidly reverses
      RV pressure overload in PE, but not increase bleeding and other adverse events. The aim of
      the study is to compare thrombolytic treatment with LMWH in patients with acute normotensive
      PE with right ventricular dysfunction(RVD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In acute pulmonary embolism (PE), normotensive patients with acute RV dysfunction on
      echocardiography or computed tomography and with myocardial troponin elevation may have an
      adverse outcome. Thrombolysis rapidly reverses RV pressure overload in PE, but it increases
      the possibility of bleeding and it remains unclear whether it may improve the early or
      long-term clinical outcome of these selected normotensive patients.

      In our previous study, we found that low dose (50mg/2h) recombinant tissue plasminogen
      activator (rt-PA) regimen had less bleeding tendency than the 100mg/2h regimen (3% vs.10%),
      it is worthwhile to reveal whether low dose rt-PA plus Low Molecular Weight Heparin (LMWH)
      can rapidly reverses RV pressure overload in PE, but not increase bleeding and other adverse
      events.

      In this prospective, multicenter, randomized, control study, we compare low dose rt-PA plus
      LMWH vs. LMWH alone in acute normotensive pulmonary embolism patients with RV dysfunction.
      The primary efficacy outcome is the composite of death from any cause or treatment failure,
      improvements of right ventricular functions on echocardiogram and pulmonary artery
      obstruction on CT angiographs within 7 days of randomization. Second efficacy outcome is the
      recurrence of pulmonary embolism and deep venous thrombosis. Safety outcomes include serious
      life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes, also
      include mild bleeding. In addition, 90-day clinical and echocardiographic follow-up will be
      performed, the recurrence of pulmonary embolism and deep venous thrombosis will be recorded.
      The study is expected to enroll approximately 460 patients.

      By determining the benefits vs risks of Low dose rt-PA plus LMWH compared with LMWH alone for
      the treatment in submassive or intermediate-risk PE, this trial is expected to reveal the
      worth of Low dose rt-PA plus LMWH treatment and what kind of PE patients are suitable for
      thrombolysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the composite end point of death from any cause or treatment failure,recurrence of VTE</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical relevant non-major bleedings</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the composite end point of death from any cause or treatment failure,recurrence of VTE</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical relevant non-major bleedings</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Pulmonary Thromboembolisms</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Low dose (50mg/2h) rt-PA plus LMWH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMWH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low molecular weight heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant tissue plasminogen activator (rt-PA)</intervention_name>
    <description>Low dose (50mg/2h) rt-PA plus LMWH</description>
    <arm_group_label>Low dose (50mg/2h) rt-PA plus LMWH</arm_group_label>
    <other_name>rt-PA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Molecular Weight Heparin</intervention_name>
    <description>0.1ml/10kg,q12h,5-7 days</description>
    <arm_group_label>LMWH</arm_group_label>
    <other_name>Nadroparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 y≤Age≤75y

          2. Acute PE (first symptoms occurred 14 d or less before randomization) confirmed by lung
             scan, or a positive computed tomographic pulmonary angiogram, or a positive selective
             pulmonary angiogram

          3. Hemodynamic stability, diastolic pressure&gt;90mmHg.

          4. RV dysfunction confirmed by echocardiography (≥1 criterion), except left-side heart
             disease, congenital heart disease and mitral valve disease.

               -  Increase of the right ventricle showed presented with RV end-diastolic
                  anteroposterior diameter &gt;25 mm, Right/left ventricular end-diastolic diameter &gt;1
                  (apical or subcostal 4-chamber view) or Right/left ventricular end-diastolic
                  anteroposterior diameter &gt;0.5

               -  Hypokinesis of RV-free wall (range of motion less than 5 mm)

               -  Tricuspid regurgitation pressure &gt;30mmHg

        Exclusion Criteria:

          1. RV anterior wall thickness &gt; 5mm confirmed by echocardiography

          2. Active internal bleeding and spontaneous intracranial hemorrhage in preceding 6 months

          3. Major surgery, organ biopsy or non-compressible punctures within 2 weeks

          4. Ischemic stroke occurred within 2 months

          5. Gastrointestinal bleeding within 10 days

          6. Severe trauma occurred within15 days

          7. Neurosurgery or eye surgery within 1 months

          8. Severe hypertension difficult to control (systolic blood pressure&gt;180mmHg or diastolic
             blood pressure&gt;110mmHg)

          9. Cardiopulmonary resuscitation

         10. Platelet count less than 100×109 / L

         11. Pregnancy, or within 2 week post partum

         12. Infective endocarditis; left atrial thrombus; aneurysm

         13. Serious liver and kidney dysfunction

         14. Diabetic hemorrhagic retinopathy

         15. Suffering with bleeding disorders

         16. Chronic thromboembolic pulmonary hypertension

         17. Moderate to severe chronic obstructive pulmonary disease (COPD).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Wang, PhD,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Wang, PhD,MD</last_name>
    <phone>8610-85231893</phone>
    <email>cyh-birm@263.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tuguang Kuang, PhD,MD</last_name>
    <phone>8610-85231451</phone>
    <email>ktg2004@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Daxing People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongxiang Zhang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yongxiang Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhihong Liu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zhihong Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital, Ministry of Health</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Baomin Fang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Baoming Fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chao Yang Hospial</name>
      <address>
        <city>Bejing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanhua Yang, PhD,MD</last_name>
      <phone>8610-65060167</phone>
      <email>yyh1031@sina.com</email>
    </contact>
    <investigator>
      <last_name>Chen Wang, PhD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuanhua Yang, PhD,MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Zhongshan University in Guangzhou</name>
      <address>
        <city>Guang Zhou</city>
        <state>GUang Dong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yulin Zhou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tiantuo Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhongshan University in Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mian Zeng, MD</last_name>
    </contact>
    <investigator>
      <last_name>Canmao Xie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Guangxi Zhuang Autonomous Region people's Hospital</name>
      <address>
        <city>Nan ning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shengze Long, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zhiqiang Qing, PhD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangzhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Qiu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chen Qiu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Chengde Medical College</name>
      <address>
        <city>Chengde</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guifang Pang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Qing Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first hospital of Handan city Hebei Province</name>
      <address>
        <city>Handan</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinghui Ye, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jinghui Ye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei Hengshui international Heping Hospital</name>
      <address>
        <city>Hengshui</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaobo Cui, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zhaobo Cui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei Affiliated Hospital of North China Coal Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baibing Liu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hongyang Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei Medical University Second Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yadong Yuan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yadong Yuan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>No.2 Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hong Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Inner Mongolia Medical College</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jingping Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Inner Mongolia Autonomous Region</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weilie Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wenting Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anshan Iron and Steel Company General Hospital</name>
      <address>
        <city>Anshan</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyu Zhou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hongyu Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingqun Ji, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zhonghe Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoning General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Shi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zhuang Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenyang Medical College affiliated Fengtian Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuyue Xia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shuyue Xia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng Yang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jin Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Jining Medical University Affiliated Hospital</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luning Jiang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luning Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Medical College Affiliated Hospital of Qiingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Tong, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zhaozhong Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Yantai city Yantai Mountain hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijun Kang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shudong Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guochao Shi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shaoguang Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Military Medical University Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Qiang Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Shanghai Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinjun Jiang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chunxue Bai, PhD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Medical University Second Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zhuola Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyun Hu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yongcheng Du, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Military Medical University, Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengqing Li, PhD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Changgui Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sichuan University, West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun Yi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Qun Yi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaiyi Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zaiyi Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Xinjiang Uygur Autonomous Region people's Hospital</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xiaohong Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guofeng Ma, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kejing Ying, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical College in Zhejiang</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yupeng Xie, MD</last_name>
    </contact>
    <investigator>
      <last_name>Liangxing Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <last_update_submitted>February 11, 2012</last_update_submitted>
  <last_update_submitted_qc>February 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Chen WANG</investigator_full_name>
    <investigator_title>Professor of respiratory and critical care medicine</investigator_title>
  </responsible_party>
  <keyword>pulmonary embolism</keyword>
  <keyword>right ventricular dysfunction</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>Heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

